Online Inquiry

Global Services. (Creative Biolabs Authorized)

Anti-CAR ADA (Anti-Drug Antibody) Assay Service

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

Creative Biolabs provides an Anti-CAR ADA (Anti-Drug Antibody) Assay Service to support comprehensive immunogenicity evaluation of CAR-based therapies. This service addresses challenges in characterizing humoral immune responses against engineered CAR molecules, predicting CAR cell clearance risks, and understanding factors affecting therapeutic persistence. Through a validated MSD electrochemiluminescence bridging assay platform, Creative Biolabs enables sensitive detection and analysis of anti-CAR antibody responses in serum or plasma samples, supporting immunogenicity assessment and translational development of CAR-T and CAR-NK programs.

Introduction

CAR-based therapies introduce engineered receptor components that may be recognized as foreign by the patient's immune system. Anti-CAR ADA analysis is an important approach for monitoring antibody-mediated immune responses against CAR extracellular domains, particularly antigen-binding regions such as scFv sequences. The anti-CAR antibody development may influence CAR cell persistence, accelerate immune-mediated clearance, and potentially reduce therapeutic activity. Therefore, sensitive and specific ADA detection strategies are valuable for evaluating the safety and durability of engineered immune cell therapies.

Service

The emergence of immune responses against engineered CAR structures represents an important consideration during the development of CAR-based therapeutics. Creative Biolabs provides Anti-CAR ADA Assay solutions designed to detect and characterize antibodies generated against CAR binding domains.

Our platform utilizes advanced MSD electrochemiluminescence bridging technology and a structured three-stage analytical framework to detect anti-CAR antibody responses in preclinical and clinical serum or plasma samples. We help researchers assess immunogenicity risks linked to engineered receptors, uncover humoral-mediated CAR cell elimination mechanisms, and compare construct profiles during candidate selection. By delivering reliable anti-drug antibody (ADA) data, this service provides the robust evidence needed for IND-enabling studies and clinical development strategies, ensuring a clear understanding of CAR persistence and therapeutic performance.

Discover How We Can Help - Request a Consultation.

What We Can Offer

Assay of Anti-CAR ADA (Anti-Drug Antibody) Assay. (Creative Biolabs Original)

Creative Biolabs provides a comprehensive Anti-CAR ADA analysis platform based on MSD electrochemiluminescence bridging assay technology. The service is designed to identify and quantify antibodies specifically recognizing CAR-derived binding domains in biological samples.

Our Workflow

Required Starting Materials:

CAR construct information, including amino acid sequence or antigen-binding domain sequence.
Biological samples, such as serum or plasma, collected from preclinical or clinical studies.
Study design information, including sampling schedule, treatment groups, and intended analysis objectives.

Workflow of Anti-CAR ADA (Anti-Drug Antibody) Assay. (Creative Biolabs Original)

Final Deliverables:

Anti-CAR ADA assay report, including screening, confirmation, and titer assay results.
Sample-by-sample ADA response analysis, including positive/negative classification and quantitative evaluation.
Technical interpretation summary, describing potential implications for CAR immunogenicity and further development strategies.

Core Benefits

Flexible service solutions for preclinical and clinical studies, supporting different research stages from early CAR candidate screening to translational and clinical immunogenicity monitoring.
Optimized assay workflows and analytical strategies, including assay parameter optimization, specificity confirmation, signal evaluation, and quantitative ADA response analysis.
High-quality data analysis and reporting provide a clear interpretation of ADA-positive samples, antibody response trends, and potential implications for CAR therapeutic development.

FAQs

Q: Why is Anti-CAR ADA testing important for CAR-based therapies?

A: Anti-CAR ADA testing helps determine whether the immune system develops antibodies against engineered CAR components. These immune responses may affect CAR cell persistence, clearance, and therapeutic performance, making ADA monitoring an important component of immunogenicity evaluation.

Q: What types of CAR molecules can be evaluated using this assay?

A: The assay can support the evaluation of CAR constructs containing different antigen-binding domains. Customized assay strategies can be developed according to CAR molecular characteristics.

Q: What samples are required for Anti-CAR ADA analysis?

A: Typical sample types include serum or plasma collected from treated subjects or experimental models. Required sample volume and collection strategy depend on study design and analytical objectives.

Partner with Us

Creative Biolabs provides specialized Anti-CAR ADA testing solutions for CAR-T, CAR-NK, and emerging engineered immune cell therapies. Through MSD electrochemiluminescence bridging assays, comprehensive ADA workflow design, and immunogenicity data interpretation, we help researchers evaluate antibody-mediated risks and support successful CAR therapeutic development. Contact us for full details on Anti-CAR ADA Assay development, sample specifications, workflow customization, and project consultations.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.